Principal Investigator
Ofelia Alvarez
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20210867
Clinical Trial Summary
An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral Etavopivat, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease
Protocol No. 4202-HEM-301
Phase
Phase II/III
Funding Agency/Sponsor
Industry
Disease
Other
Contact Information
Study Contact
Grace Alvarez
Phone Number
+1 (305) 2434447
Email
galvarez2@miami.edu